Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

158TiP - BioItaLEE: Molecular features of postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–) PIK3CA-mutated advanced breast cancer (ABC) on first-line treatment with ribociclib + letrozole and on second-line treatment with alpelisib + fulvestrant

Date

17 Sep 2020

Session

E-Poster Display

Topics

Targeted Therapy

Tumour Site

Breast Cancer

Presenters

Giacomo Allegrini

Citation

Annals of Oncology (2020) 31 (suppl_4): S274-S302. 10.1016/annonc/annonc266

Authors

G. Allegrini1, M. Orditura2, L. Del Mastro3, C. Zamagni4, R. Torrisi5, V. Guarneri6, I. Paris7, G. Sarobba8, F. Puglisi9, M.A. Colleoni10, F. Montemurro11, A. Zambelli12, M.E. Cazzaniga13, M.R. Valerio14, G. Bianchi15, E. Romagnoli16, M. Caruso17, S. Cinieri18, D. Castelletti19, G. Arpino20

Author affiliations

  • 1 U.o.c. Oncologia Medica, Presidio Ospedaliero Livorno, 57123 - Livorno/IT
  • 2 U.o.c. Oncologia Medica E Ematologia, A.O.U. Università Degli Studi L. Vanvitelli, 80131 - Napoli/IT
  • 3 U.o.s.d. Breast Unit, I.R.C.C.S. Ospedale Policlinico San Martino, 16132 - Genoa/IT
  • 4 S.s.d. Oncologia Medica Addarii, Policlinico Sant’Orsola-Malpighi, 40138 - Bologna/IT
  • 5 Oncology, Humanitas Clinical and Research Center- IRCCS, 20089 - Rozzano/IT
  • 6 Dipartimento Di Scienze Chirurgiche, Oncologiche E Gastroenterologiche, Università di Padova; Oncologia Medica 2, Istituto Oncologico Veneto IOV IRCCS, 35128 - Padova/IT
  • 7 Department Of Woman And Child Sciences, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, 00168 - Rome/IT
  • 8 Uoc Oncologia, Presidio Ospedaliero S. Francesco, ASL Nuoro, 08100 - Nuoro/IT
  • 9 S.o.c. Oncologia Medica E Prevenzione Oncologica, IRCCS, Centro di Riferimento Oncologico, 33081 - Aviano/IT
  • 10 Senologia Medica, IEO, Istituto Europeo di Oncologia, IRCCS, 20141 - Milano/IT
  • 11 Istituto Di Candiolo, FPO, IRCCS, Candiolo, 10060 - Torino/IT
  • 12 U.s.c Oncologia, Presidio Ospedaliero Papa Giovanni XXIII, 24127 - Bergamo/IT
  • 13 Phase 1 Research Centre, University of Milano Bicocca, 20900 - Monza/IT
  • 14 U.o.c. Oncologia Medica, Az. Ospedaliera Universitaria Policlinico P. Giaccone, 90127 - Palermo/IT
  • 15 Fondazione Irccs, Istituto Nazionale Tumori Milano, 20133 - Milano/IT
  • 16 U.o.c. Oncologia, Presidio Ospedaliero di Macerata, 62100 - Macerata/IT
  • 17 U.o.c. Oncologia Medica, Humanitas Centro Catanese di Oncologia, 95125 - Catania/IT
  • 18 U.o.c. Oncologia Medica, Presidio Ospedaliero A. Perrino, 72100 - Brindisi/IT
  • 19 Oncology, Novartis Farma SpA, 21040 - Origgio/IT
  • 20 Dipartimento Di Clinica Medica E Chirurgia, Università Federico II, 80131 - Napoli/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 158TiP

Background

In SOLAR-1 trial (NCT02437318), patients (pts) with HR+/HER2–, PIK3CA-mutated ABC treated with alpelisib + fulvestrant showed a prolonged progression free survival (PFS) vs pts treated with fulvestrant alone who were previously treated with a CDK4/6 inhibitor (9 pts). Additional biomolecular data would be useful to help clinicians in defining an optimal personalized treatment strategy.

Trial design

BioItaLEE, a phase IIIb, open-label, Italian, multicenter study (NCT03439046) includes two phases: a core phase that enrolled 287 postmenopausal pts with HR+, HER2– ABC treated in first-line with ribociclib + letrozole and an extension phase (introduced by a protocol amendment), which is now enrolling PIK3CA-mutated pts who had progressed on the core phase and now they will be treated in second-line with alpelisib and fulvestrant. Here, we present the extension phase trial design and its current status. Similar to the core phase, biological samples will be prospectively collected at different time points as follows: liquid biopsies at baseline, cycle 1 day 15, cycle 2 day 1, at first imaging evaluation, and upon disease progression; and also newly obtained tissue biopsies at baseline, and at progression. The primary objective is to identify the circulating tumor DNA (ctDNA) alterations at baseline, to describe their evolution during treatment, and to evaluate the association with clinical outcome. An optimized next-generation sequencing approach for the detection of low abundance events in ctDNA is adopted. The secondary objectives include the evaluation of ctDNA alterations at time of tumor progression, tumor microenvironment, PFS on second-line treatment, clinical efficacy and safety. The exploratory objectives include pharmacogenomics and drug-drug interactions. A descriptive statistics will be applied. The first extension phase patient was screened on September 4, 2019, and as of April 2020, 10 PIK3CA-mutated pts have been enrolled. Enrollment is ongoing.

Clinical trial identification

NCT03439046.

Editorial acknowledgement

Legal entity responsible for the study

Novartis Farma SpA, Origgio, Italy.

Funding

Novartis Farma SpA, Origgio, Italy.

Disclosure

L. Del Mastro: Honoraria (self), Personal fees: Roche; Honoraria (self), Personal fees: Pfizer; Honoraria (self), Personal fees: Ipsen; Honoraria (self), Personal fees: Eli Lilly; Honoraria (self), Personal fees: Novartis; Honoraria (self), Personal fees: Takeda; Honoraria (self), Personal fees: MSD; Honoraria (self), Personal fees: Genomic Health; Honoraria (self), Personal fees: Celgene; Honoraria (self), Personal fees: Seattle Genetics. C. Zamagni: Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses, Grant, personal fees and non-financial support: Roche; Advisory/Consultancy, Grant: Eisai; Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses, Grant, personal fees and non-financial support: Novartis; Advisory/Consultancy, Research grant/Funding (self), Grant, personal fees and non-financial support: AstraZeneca; Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses, Grant, personal fees and non-financial support: Pfizer; Advisory/Consultancy, Travel/Accommodation/Expenses, Grant: PharmaMar; Advisory/Consultancy, Travel/Accommodation/Expenses, Grant: Celgene; Advisory/Consultancy, Grant: Lilly; Advisory/Consultancy, Grant, personal fees: Amgen; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses, Grant, personal fees: Tesaro; Advisory/Consultancy, Personal fees: QuintikesIMS; Research grant/Funding (institution), Travel/Accommodation/Expenses, Grant: PierreFabre; Research grant/Funding (institution), Travel/Accommodation/Expenses, Grant: Istituto Gentili; Research grant/Funding (institution), Grant: Takeda; Research grant/Funding (institution), Grant: TEVA; Research grant/Funding (institution), Grant: Medivation; Research grant/Funding (institution), Grant: Abbvie; Research grant/Funding (institution), Grant: Array BioPharma; Research grant/Funding (institution), Grant: Morphotek; Research grant/Funding (institution), Grant: Synthon; Research grant/Funding (institution), Grant: Seattle Genetics. V. Guarneri: Advisory/Consultancy, Speaker Bureau/Expert testimony, Personal fees: Eli Lilly; Advisory/Consultancy, Speaker Bureau/Expert testimony, Personal fees: Novartis; Advisory/Consultancy, Research grant/Funding (institution), Grant, personal fees: Roche. F. Puglisi: Honoraria (self), Personal fees: Amgen; Research grant/Funding (institution), Grant: Astrazeneca; Travel/Accommodation/Expenses, Others: Celgene; Research grant/Funding (institution), Grant, others: Eisai; Research grant/Funding (institution): Eli Lilly; Honoraria (self), Personal fees: MSD; Honoraria (self), Personal fees: Novartis; Honoraria (self), Personal fees: Pierre-Fabre; Research grant/Funding (institution), Travel/Accommodation/Expenses, Grant, personal fees and other: Roche; Honoraria (self), Grant: Takeda. M.A. Colleoni: Advisory/Consultancy, Personal fees: Novartis. F. Montemurro: Honoraria (self), Personal fees: Novartis; Honoraria (self), Personal fees: Roche; Honoraria (self), Personal fees: Pfizer; Honoraria (self), Personal fees: Eli Lilly; Honoraria (self), Personal fees: Daiichi Sankyo; Honoraria (self), Personal fees: Pierre Fabre. A. Zambelli: Honoraria (self): Novartis; Honoraria (self): Pfizer; Honoraria (self): Eli Lilly; Honoraria (self): Roche; Honoraria (self): AstraZeneca. G. Bianchi: Advisory/Consultancy, Personal fees: Novartis; Advisory/Consultancy, Personal fees: Eli Lilly. D. Castelletti: Full/Part-time employment: Novartis. G. Arpino: Honoraria (self), Grant, personal fees: Roche; Honoraria (self), Personal fees: Lilly; Honoraria (self), Grant, personal fees, non-financial support: Pfizer; Honoraria (self), Personal fees: Amgen; Honoraria (self), Grant, personal fees: Eisai; Advisory/Consultancy, Personal fees, non-financial support: Novartis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.